Nonalcoholic fatty liver disease (NAFLD) is increasingly concerning due to fat buildup in the liver, often related to obesity and inflammation; this study focuses on using silymarin-supplemented cookies as a potential treatment.
A clinical trial with 64 NAFLD patients assessed the effects of these cookies on liver enzyme activity, inflammatory markers, and lipid profiles over three months, comparing treatment groups with a placebo.
Results showed significant improvements in liver enzymes and inflammatory markers in the treatment groups, particularly the third group, highlighting silymarin's potential benefits for managing NAFLD.